Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) Save

Date Added
March 10th, 2020
PRO Number
Pro00095068
Researcher
Patrick O'neil

List of Studies


Profiles_link
Keywords
Drug Studies, Obesity, Weight Control
Summary

Tirzepatide is an investigational medication that has been studied for the treatment of diabetes when administered once a week by self-injection. In these trials people who received the medication also lost some weight. This study is being done to see how safe tirzepatide is and how well it will work to help people who are obese or overweight to lose weight, when it is used along with a reduced-calorie diet and increased physical activity.

Participants will be randomly assigned to one of three doses of tirzepatide or to a placebo (inactive look-alike drug). They will be followed for either 72 or 176 weeks depending on the results of an initial test of blood sugar control.

Institution
MUSC
Recruitment Contact
Mary Harley
843-792-5428
harleyma@musc.edu

Effect and safety of subcutaneous semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in subjects with overweight or obesity Save

Date Added
September 18th, 2019
PRO Number
Pro00091527
Researcher
Patrick O'neil

List of Studies


Profiles_link
Keywords
Drug Studies, Obesity, Weight Control
Summary

This is a 76-week trial comparing semaglutide 2.4 mg taken once weekly with liraglutide 3.0 mg taken once daily as an adjunct to a reduced-calorie diet and increased physical activity in subjects with overweight or obesity . This is a randomized, double-blinded trial. Each active medication will be compared against a placebo and be administered per a dosing schedule.

Institution
MUSC
Recruitment Contact
Mary Harley
843-792-5428
harleyma@musc.edu

A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH) Save

Date Added
February 28th, 2017
PRO Number
Pro00062843
Researcher
David Koch

List of Studies


Profiles_link
Keywords
Disease Prevention, Genetics, Liver, Obesity, Weight Control
Summary

This is a 5-year, longitudinal, observational study of patients with NAFL or NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, a bio specimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.

Institution
MUSC
Recruitment Contact
Francis Beylotte
843-876-4273
beylott@musc.edu

A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma Save

Date Added
February 28th, 2017
PRO Number
Pro00062918
Researcher
David Koch

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Gastrointestinal, Cancer/Other, Digestive System, Genetics, Liver, Obesity, Weight Control
Summary

TARGET-HCC is a 5-year, longitudinal, observational study of the natural history and management of patients with HCC. The study will address important clinical questions that remain unanswered in the management of HCC with a unique research registry of participants with HCC from academic and community real-world practices. TARGET-HCC is disease focused, not drug specific, which allows for continuous acquisition of real-world evidence regarding the natural history, management, and outcomes of treatment with current therapies and new treatments that may be utilized in usual clinical practice.

Institution
MUSC
Recruitment Contact
Francis Beylotte
843-876-4273
beylott@musc.edu

Change_preferences

-- OR --

Create_login